Balchem (NASDAQ:BCPC) Given New $185.00 Price Target at HC Wainwright

Balchem (NASDAQ:BCPC) had its target price hoisted by HC Wainwright from $170.00 to $185.00 in a research note released on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Balchem’s Q1 2025 earnings at $1.04 EPS, Q2 2025 earnings at $1.08 EPS, Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.16 EPS and FY2025 earnings at $4.40 EPS.

Separately, StockNews.com cut shares of Balchem from a buy rating to a hold rating in a report on Monday, July 29th.

Balchem Trading Down 2.6 %

Shares of BCPC stock opened at $171.47 on Wednesday. Balchem has a 12-month low of $110.74 and a 12-month high of $186.03. The company has a current ratio of 2.83, a quick ratio of 1.79 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average is $160.72 and its 200 day moving average is $153.33. The stock has a market capitalization of $5.56 billion, a P/E ratio of 47.97, a P/E/G ratio of 5.67 and a beta of 0.67.

Balchem (NASDAQ:BCPC) last issued its earnings results on Friday, May 3rd. The basic materials company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Balchem had a return on equity of 10.94% and a net margin of 12.52%. The company had revenue of $239.66 million during the quarter, compared to analysts’ expectations of $234.12 million. Research analysts expect that Balchem will post 3.91 earnings per share for the current year.

Insiders Place Their Bets

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total value of $1,395,387.50. Following the transaction, the senior vice president now directly owns 8,540 shares in the company, valued at $1,537,627. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director David B. Fischer sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $152.98, for a total transaction of $764,900.00. Following the sale, the director now directly owns 9,009 shares in the company, valued at approximately $1,378,196.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Gunsteren Job Leonard Van sold 7,750 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the sale, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,679 shares of company stock worth $2,458,222. Company insiders own 1.25% of the company’s stock.

Institutional Trading of Balchem

Several institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC increased its holdings in Balchem by 123.0% in the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after acquiring an additional 91 shares during the last quarter. Principal Securities Inc. bought a new stake in Balchem in the 4th quarter valued at $28,000. Bessemer Group Inc. increased its holdings in Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after acquiring an additional 256 shares during the last quarter. GAMMA Investing LLC bought a new stake in Balchem in the 4th quarter valued at $56,000. Finally, YHB Investment Advisors Inc. bought a new stake in Balchem in the 1st quarter valued at $69,000. 87.91% of the stock is currently owned by institutional investors.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.